Principal Financial Group Inc. Buys 146,621 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Principal Financial Group Inc. boosted its position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 102.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 290,414 shares of the company's stock after buying an additional 146,621 shares during the quarter. Principal Financial Group Inc. owned approximately 0.14% of Hims & Hers Health worth $5,349,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. CWM LLC grew its holdings in Hims & Hers Health by 21.4% during the third quarter. CWM LLC now owns 5,982 shares of the company's stock valued at $110,000 after purchasing an additional 1,054 shares during the period. Arizona State Retirement System boosted its holdings in shares of Hims & Hers Health by 3.0% in the second quarter. Arizona State Retirement System now owns 40,344 shares of the company's stock valued at $815,000 after purchasing an additional 1,173 shares during the period. Victory Capital Management Inc. raised its position in shares of Hims & Hers Health by 6.6% in the 2nd quarter. Victory Capital Management Inc. now owns 19,469 shares of the company's stock valued at $393,000 after purchasing an additional 1,212 shares during the last quarter. Nisa Investment Advisors LLC increased its holdings in Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company's stock valued at $37,000 after buying an additional 1,603 shares in the last quarter. Finally, ProShare Advisors LLC boosted its holdings in shares of Hims & Hers Health by 10.0% during the 1st quarter. ProShare Advisors LLC now owns 22,257 shares of the company's stock worth $344,000 after purchasing an additional 2,023 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on HIMS shares. Bank of America lowered shares of Hims & Hers Health from a "buy" rating to an "underperform" rating and cut their price objective for the stock from $32.00 to $18.00 in a report on Thursday, November 14th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a "hold" rating in a report on Wednesday, November 6th. Needham & Company LLC assumed coverage on Hims & Hers Health in a research note on Thursday, August 22nd. They set a "buy" rating and a $24.00 target price for the company. Piper Sandler reissued a "neutral" rating and set a $21.00 price objective (up from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. Finally, Imperial Capital lowered Hims & Hers Health from an "outperform" rating to an "in-line" rating in a research note on Friday, August 9th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $20.71.

Insider Activity at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 142,886 shares of the business's stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $29.93, for a total transaction of $4,276,577.98. Following the completion of the transaction, the chief financial officer now owns 112,186 shares in the company, valued at approximately $3,357,726.98. The trade was a 56.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Christiane Pendarvis sold 7,000 shares of the stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $15.15, for a total transaction of $106,050.00. Following the completion of the sale, the director now directly owns 23,917 shares in the company, valued at approximately $362,342.55. The trade was a 22.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,056,183 shares of company stock valued at $21,501,682. Insiders own 17.71% of the company's stock.

Hims & Hers Health Stock Up 3.8 %

Shares of NYSE HIMS traded up $0.82 during mid-day trading on Thursday, reaching $22.61. 13,427,107 shares of the company were exchanged, compared to its average volume of 9,441,367. Hims & Hers Health, Inc. has a 1 year low of $7.67 and a 1 year high of $30.44. The stock has a market cap of $4.94 billion, a price-to-earnings ratio of 49.55 and a beta of 1.06. The firm has a 50-day moving average of $20.21 and a 200 day moving average of $19.09.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.06 by $0.26. The business had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm's revenue was up 77.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.04) earnings per share. On average, equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.